

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective
August 1, 2003
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR
NEWS 10 SEP 22 DIPPR file reloaded
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded
NEWS 12 SEP 29 DISSABS now available on STN
NEWS 13 OCT 10 PCTFULL: Two new display fields added
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 16 NOV 24 MSDS-CCOHS file reloaded

NEWS EXPRESS NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:50:27 ON 03 DEC 2003

=> file polymers, medline, biosis, embase
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'APOLLIT' ENTERED AT 08:50:52 ON 03 DEC 2003

COPYRIGHT (c) 2003 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 08:50:52 ON 03 DEC 2003

COPYRIGHT (c) 2003 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 08:50:52 ON 03 DEC 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 08:50:52 ON 03 DEC 2003

COPYRIGHT (c) 2003 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEN' ENTERED AT 08:50:52 ON 03 DEC 2003

COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 08:50:52 ON 03 DEC 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'DISSABS' ENTERED AT 08:50:52 ON 03 DEC 2003

COPYRIGHT (C) 2003 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 08:50:52 ON 03 DEC 2003

COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 08:50:52 ON 03 DEC 2003

COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 08:50:52 ON 03 DEC 2003

COPYRIGHT (C) 2003 Japan Science and Technology Agency (JST)

FILE 'PASCAL' ENTERED AT 08:50:52 ON 03 DEC 2003

Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PLASNEWS' ENTERED AT 08:50:52 ON 03 DEC 2003

Copyright (C) 2003 Bill Communications, Inc. (BCI)

FILE 'PROMT' ENTERED AT 08:50:52 ON 03 DEC 2003

COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 08:50:52 ON 03 DEC 2003

COPYRIGHT (C) 2003 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 08:50:52 ON 03 DEC 2003

COPYRIGHT 2003 THOMSON ISI

FILE 'TEXTILETECH' ENTERED AT 08:50:52 ON 03 DEC 2003

COPYRIGHT (C) 2003 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 08:50:52 ON 03 DEC 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 08:50:52 ON 03 DEC 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ENTERED AT 08:50:52 ON 03 DEC 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WTEXTILES' ENTERED AT 08:50:52 ON 03 DEC 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'MEDLINE' ENTERED AT 08:50:52 ON 03 DEC 2003

FILE 'BIOSIS' ENTERED AT 08:50:52 ON 03 DEC 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 08:50:52 ON 03 DEC 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

=> s heparin
L1 326717 HEPARIN

=> s l1 and (motoneuron or amyotroph?(w)sclerosis or muscular(w)atroph? or lateral(w)sclerosis)

20 FILES SEARCHED...

L2 1679 L1 AND (MOTONEURON OR AMYOTROPH?(W) SCLEROSIS OR MUSCULAR(W)
ATROPH? OR LATERAL(W) SCLEROSIS)

=> s l2 and treat?

19 FILES SEARCHED...

L3 1618 L2 AND TREAT?

=> s l3 and (enoxaparin or nadroparin or parnaparin or reviparin or dalteparin or tinzaparin or danaparoid or ardeparin or certoparin)

22 FILES SEARCHED...

L4 33 L3 AND (ENOXAPARIN OR NADROPARIN OR PARNAPARIN OR REVIPARIN OR
DALTEPARIN OR TINZAPARIN OR DANAPAROID OR ARDEPARIN OR CERTOPARI
N)

=> dis l4 1-33 bib abs

L4 ANSWER 1 OF 33 CBNB COPYRIGHT 2003 EI on STN
AN 14(17):24635 CBNB
TI Rhone-Poulenc Rorer announces measures to improve productivity.
SO (23 Apr 1998), (200-899 words)
Availability: Rhone-Poulenc Rorer, France. Tel: 011-33-1-55-71-63-60;
Fax: 800-758-5804 Ext: 764050; Website: <http://www.rp-rorer.com>
DT Press Release
LA English
PY 1998
AB Rhone-Poulenc Rorer, a global pharmaceutical subsidiary of Rhone-Poulenc SA announced initiatives to improve its productivity. These initiatives will impact Rhone-Poulenc Rorer's two headquarters in Antony, France, and in Collegeville, PA, in the US, and Vitry (France) research and manufacturing sites. These reorganizational efforts are part of a reengineering programme announced by the company in end Jan 1998 to simplify and decentralize its organization, improve profitability, reduce operating costs and accelerate the growth of new products. Some new products being undertaken for development include Taxotere (docetaxel), a chemotherapy agent; Lovenox/Clexane (**enoxaparin** sodium), the world's leading low-molecular- weight **heparin**; Nasacort (triamcinolone acetonide), for the **treatment** of seasonal or perennial allergic rhinitis; and Rilutek (riluzole), for the **treatment** of ALS (amyotrophic lateral sclerosis). Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to improving human and animal health.

L4 ANSWER 2 OF 33 IFIPAT COPYRIGHT 2003 IFI on STN
AN 10096447 IFIPAT;IFIUDB;IFICDB
TI NOVEL THERAPEUTIC USE OF LOW MOLECULAR WEIGHT **HEPARINS**; LOW

MOLECULAR WEIGHT **HEPARIN** CONSISTS OF OLIGOSACCHARIDES HAVING A
2-O-SULFO-4-ENOPYRANOSURONIC ACID AT ONE OF THEIR ENDS AND OBTAINED BY
DEPOLYMERIZATION OF A **HEPARIN** ESTER USING SODIUM HYDROXIDE
BASE; USEFUL FOR **TREATING MUSCULAR ATROPHY**

INF Stutzmann; Jean-Marie, Villecresnes, FR
Uzan; Andre, Paris, FR
IN Stutzmann Jean-Marie (FR); Uzan Andre (FR)
PAF Unassigned
PA Unassigned Or Assigned To Individual (68000)
AG AVENTIS PHARMACEUTICALS, INC. PATENTS DEPARTMENT, ROUTE 202-206, P.O. BOX
6800, BRIDGEWATER, NJ, 08807-0800, US
PI US 2002040013 A1 20020404
AI US 2001-881267 20010614
PRAI FR 1998-15919 19981217
FI US 2002040013 20020404
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 19
AB The invention concerns the use of low molecular weight **heparin**
for preventing and/or **treating** motor neuron diseases.
CLMN 19

L4 ANSWER 3 OF 33 PROMT COPYRIGHT 2003 Gale Group on STN

AN 1999:208043 PROMT
TI Best PIPELINES.
AU Engel, Styli
SO Med Ad News, (March 1999) Vol. 18, No. 3, pp. 1(1).
ISSN: 0745-0907.
PB Engel Communications, Inc.
DT Newsletter
LA English
WC 41331
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB Focus on large and unsatisfied markets, best-in-class medicines,
billion-dollar budgets, discovery, and swiftness to market are just a few
of the demands of an impressive pipeline
THIS IS THE FULL TEXT: COPYRIGHT 1999 Engel Communications Inc.

L4 ANSWER 4 OF 33 PROMT COPYRIGHT 2003 Gale Group on STN

AN 1998:202504 PROMT
TI Rhone-Poulenc Rorer Announces Measures to Improve Productivity
SO PR Newswire, (23 Apr 1998) pp. 423PHTH014.
LA English
WC 360
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB COLLEGEVILLE, Pa., and ANTONY (Paris), France, April 23 /PRNewswire/ --
Rhone-Poulenc Rorer, a global pharmaceutical subsidiary of Rhone-Poulenc
S.A. (NYSE: RP), today announced initiatives aimed at improving the
company's productivity. These initiatives will impact Rhone-Poulenc
Rorer's two headquarters in Antony, France, and in Collegeville,
Pennsylvania, in the United States, as well as the Vitry (France) research
and manufacturing sites.
Union representatives at the Antony and Vitry sites have been informed
regarding 345 redundancies and the corresponding social measures (for
example, reassignment, outplacement, retraining).
With regard to the Collegeville site, there are 78 redundancies primarily
in corporate and administrative functions. Support, including a severance
package and outplacement services, will be provided to employees impacted
by the job reductions.
These reorganizational efforts are part of a reengineering program
announced by Rhone-Poulenc at the end of January. The program was

undertaken to simplify and decentralize Rhone-Poulenc Rorer's organization, improve the company's profitability, reduce operating costs and accelerate the growth of new products such as Taxotere(R) (docetaxel), a chemotherapy agent; Lovenox(R)/Clexane(R) (**enoxaparin** sodium), the world's leading low-molecular-weight **heparin**; Nasacort(R) (triamcinolone acetonide), for the **treatment** of seasonal or perennial allergic rhinitis; and Rilutek(R) (riluzole), for the **treatment** of ALS (amyotrophic **lateral sclerosis**).

Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to improving human health. Rhone-Poulenc S.A. is a leading life sciences company, growing through innovations in human, plant and animal health and through its specialty chemicals subsidiary, Rhodia. With sales in 1997 of FF90 billion (U.S. \$15 billion), the company employs 68,000 people in 160 countries.

/EDITORS' ADVISORY: This press release was issued earlier today in France by Rhone-Poulenc Rorer, a subsidiary of Rhone-Poulenc S.A. (NYSE: RP)./
/CONTACT: Media, (France) Rossella Daverio, 011-33-1-55-71-63-60, or (U.S.) John H. Abrams, 610-454-5452; or Investors, Arvind Sood, 011-33-1-47-68-14-08, or Dwight Grimestad, 732-821-3316, all of Rhone-Poulenc Rorer/
/Company News On-Call: <http://www.prnewswire.com> or fax, 800-758-5804, ext. 764050/

THIS IS AN EXCERPT: COPYRIGHT 1998 PR Newswire Association, Inc.

L4 ANSWER 5 OF 33 PROMT COPYRIGHT 2003 Gale Group on STN

AN 97:246267 PROMT

TI Centeon Affects Rhone-Poulenc Rorer's First Quarter Earnings; RPR Reports First Quarter Earnings of 41 Cents a Share

SO PR Newswire, (24 Apr 1997) pp. 424PHTH019.

LA English

WC 1328

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB COLLEGEVILLE, Pa., and PARIS, April 24 /PRNewswire/ -- Rhone-Poulenc Rorer Inc. (NYSE: RPR) reported net income of \$57 million or 41 cents per share for the first quarter of 1997, compared with a year-ago profit of \$74 million or 55 cents a share. As expected, Centeon, a joint venture plasma proteins company of which RPR owns 50%, had a slightly negative contribution to RPR's earnings during the quarter. Excluding Centeon's contribution in both the first quarter of 1997 and the comparable period a year ago, earnings per share would have risen 33%. Reported sales of \$1.086 billion during the first quarter were affected significantly by product divestitures and currency fluctuations. RPR divested several non-strategic products during 1996, which reduced sales by 9 percentage points during the first quarter. The significant strengthening of the dollar also penalized sales by an additional 6 percentage points. Excluding the impact of divestitures and currency fluctuations, sales were unchanged during the quarter as compared to the same quarter in the previous year. Wholesaler buying patterns in the US as well as weakness in European markets resulting from health care reforms in France and Germany affected RPR's overall business during the quarter. Product mix, productivity improvements and the beneficial impact of divesting non-strategic products led to significant improvement in gross margin which rose over 4 percentage points to 70% for the quarter. Operating income rose 5% for the first quarter of 1997, mainly due to improvement in gross margin, and operating margin rose over 2 percentage points to 12%.

"We continue to implement our strategy of building a focused portfolio of products and concentrate on improving our profitability," said Michel de Rosen, Chairman & CEO. "We are building product concentration by divesting non-strategic products and the impact of these divestitures on margin improvement is apparent. I am confident in our future outlook."

Our Board of Directors has authorized the repurchase of up to 5 million RPR shares," declared de Rosen.

"The delay in resuming distribution of Centeon products has been disappointing for RPR and its shareholders, but Centeon is implementing the necessary enhancements at its Kankakee, Illinois facility, and will continue to work closely with the FDA in an effort to resume distribution of its products manufactured at this facility into the marketplace," concluded de Rosen.

THIS IS AN EXCERPT: COPYRIGHT 1997 PR Newswire Association, Inc.

L4 ANSWER 6 OF 33 PROMT COPYRIGHT 2003 Gale Group on STN

AN 97:217303 PROMT

TI Size Follows Strength, Part 1

Its new chairman and CEO, Michel de Rosen, is interviewed

AU Koberstein, Wayne

SO Pharmaceutical Executive, (Apr 1997) pp. 44.

ISSN: 0279-6570.

LA English

WC 1538

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB Michel de Rosen of Rhone-Poulenc Rorer

Sun-speckled skyscrapers retreat below as the helicopter rises from midtown Manhattan into a cloudless morning, then follows the East River south. Leapfrogging over Brooklyn, the craft alights at Kennedy to pick up two executives fresh off the Concorde from Paris. Then it climbs into the blue sky again, angles over the Statue of Liberty, and heads southwest across New Jersey to Pennsylvania. Forty minutes later it lands and deposits the passengers at the Collegeville headquarters of Rh6ne-Poulenc Rorer (RPR).

Another unique marriage of cultures in the pharmaceutical industry, this Franco-American company--now with a major British acquisition--makes extensive transatlantic and helicopter shuttles to keep its global executives in touch with its rural Pennsylvania headquarters. Ferrying a visiting editor poses few additional logistics.

We are here to speak with RPR's new chairman and CEO, Michel de Rosen. In May 1996, then president & CEO deRosen took over the chairman's job from retiring Rob Cawthorn.

French-born de Rosen reveals how his company is welding together its disparate cultural components. He also details the company's strategies for remaining one of the "eaters" instead of the "eaten" in the industry's current feast of mergers and acquisitions.

RPR's own takeover of Fisons, joint venture with Hoechst in the blood-products leader Centeon, and formation of a vast gene-therapy research network are only some of the moves the company hopes will keep it strong and independent. Through that strength, RPR hopes to raise its pharmaceutical business to a scale others have reached only by megamergers.

Signs of growth have already crested the horizon. New products such as the amyotrophic **lateral sclerosis**, or ALS, **treatment** Rilutek (riluzole), anticancer Taxotere (docetaxel), and low-molecular-weight **heparin** Lovenox (**enoxaparin**) make up the first wave of advances toward the company's targeted leadership in five therapeutic areas. Those are respiratory and allergy, plasma proteins, thrombosis and cardiovascular diseases, oncology, and anti-infectives. RPR targets two other areas--hormone replacement and central nervous system (CNS) disorders--with more limited but prominent product lines.

Strategic acquisitions, partnerships, and divestitures also play the role of prime mover in RPR's growth strategy.

THIS IS AN EXCERPT: COPYRIGHT 1997 Advanstar Communications Inc

L4 ANSWER 7 OF 33 PROMT COPYRIGHT 2003 Gale Group on STN

AN 96:486801 PROMT
TI R-PR Divulges R&D Pipeline Developments
SO Marketletter, (23 Sep 1996) pp. N/A.
ISSN: 0951-3175.
LA English
WC 1304

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB Rhone-Poulenc Rorer has revealed details of its product pipeline and further strategies for research at a meeting in Paris, on September 17. The news was well-received by the investment community, and the company's share price was boosted. R-PR has reduced the number of research projects on which it is working from 50 to 26, to concentrate on what it sees as the more promising pharmaceutical compounds and to speed up the global registration process. It also aims to put 40 new targets through screening each year and to achieve the introduction of one or two New Chemical Entities from this group. New Product Indications In oncology, indications of R-PR's flagship compound Taxotere (docetaxel) for solid tumors are to be extended to include head and neck, sarcoma and gastric cancers. These are all in Phase II or III trials. Also at this stage are studies for the first-line **treatment** of breast cancer and the second-line **treatment** of lung cancer. Taxotere will be launched in Japan in the near future for breast and non-small cell lung cancer. Indications for Lovenox/Clexane (**enoxaparin**), a low molecular-weight **heparin**, are to be expanded to combat arterial as well as venous thrombosis. Lovenox has just entered Phase I clinical trials for stroke and is in Phase II for coronary stent, and the company is to file a New Drug Application for the product in unstable angina in first-quarter 1997 in Europe, and in the same period 1998 in the USA. Sales for the global thrombosis market are expected to rise \$3.4 billion from \$4.2 billion (1995) by the year 2000. Rilutek (riluzole), for the extension of life in persons with ALS (Marketletter June 17), is being followed-up by another compound from the same chemical class, but for a number of different indications including Huntingdon's disease (to reduce motor disturbances and increase cognitive function), Parkinson's disease (for symptom reduction) and for stroke victims (to increase survival). A clinical trial is due to start in HD patients next year, and an intravenous form of the drug is in development for stroke. New cardiovascular products include: - RPR 109891, a GPIIb/IIIa antagonist in Phase II trials. It is administered orally twice-daily, and works to block platelet aggregation after infarction and regardless of stimulus.

THIS IS AN EXCERPT: COPYRIGHT 1996 Marketletter Publications Ltd. (UK)

L4 ANSWER 8 OF 33 USPATFULL on STN

AN 2003:312692 USPATFULL

TI Phosphorus-containing compounds and uses thereof

IN Berstein, David L., Waban, MA, UNITED STATES

Metcalfe, Chester A., III, Needham, MA, UNITED STATES

Rozamus, Leonard W., Bedford, MA, UNITED STATES

Wang, Yihan, Newton, MA, UNITED STATES

PI US 2003220297 A1 20031127

AI US 2003-357152 A1 20030203 (10)

PRAI US 2002-353252P 20020201 (60)

US 2002-426928P 20021115 (60)

US 2002-428383P 20021122 (60)

US 2002-433930P 20021217 (60)

DT Utility

FS APPLICATION

LREP David L. Berstein, ARIAD Gene Therapeutics, Inc., 26 Landsdowne Street, Cambridge, MA, 02139-4234

CLMN Number of Claims: 39

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3696

AB This invention concerns a new family of phosphorus-containing compounds

containing a moiety JQA--in which:

A is absent or is --O--, --S-- or --NR.sup.2--;

Q is absent or (if A is --O--, --S-- or --NR.sup.2--) Q may be --V--, --OV--, --SV--, or --NR.sup.2V--, where V is an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, such that J is linked to the cyclohexyl ring directly, through A or through VA, OVA, SVA or NR.sup.2VA; ##STR1##

K is O or S;

each occurrence of Y is independently --O--, --S--, --NR.sup.2--, or a chemical bond linking a R.sup.5 moiety to P;

and the other variables are as defined herein.

L4 ANSWER 9 OF 33 USPATFULL on STN
AN 2003:258442 USPATFULL
TI Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
IN Lai, Ching-San, Carlsbad, CA, UNITED STATES
Vassilev, Vassil P., San Diego, CA, UNITED STATES
PA Medinox, Inc. (U.S. corporation)
PI US 2003181495 A1 20030925
AI US 2003-394794 A1 20030321 (10)
RLI Continuation-in-part of Ser. No. US 2002-44096, filed on 11 Jan 2002, GRANTED, Pat. No. US 6596770 Division of Ser. No. US 2000-565665, filed on 5 May 2000, GRANTED, Pat. No. US 6589991 Division of Ser. No. US 1998-103639, filed on 23 Jun 1998, GRANTED, Pat. No. US 6093743
DT Utility
FS APPLICATION
LREP FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 2591
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel combinations of dithiocarbamate disulfide dimers with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with a thiazolidinedione for the **treatment** of diabetes. In another embodiment, In another embodiment, invention combinations further comprise additional active agents such as, for example, metformin, insulin, sulfonylureas, and the like. In another embodiment, the present invention relates to compositions and formulations useful in such therapeutic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 33 USPATFULL on STN
AN 2003:238400 USPATFULL
TI Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha-synuclein, or polyglutamine repeats for induction of an immune response thereto
IN Frangione, Blas, New York, NY, UNITED STATES
Wisniewski, Thomas, Statent Island, NY, UNITED STATES
Sigurdsson, Einar M., New York, NY, UNITED STATES
PA NEW YORK UNIVERSITY (U.S. corporation)
PI US 2003166558 A1 20030904
AI US 2002-301488 A1 20021121 (10)
PRAI US 2001-331801P 20011121 (60)
DT Utility

FS APPLICATION
LREP DARBY & DARBY P.C., Post Office Box 5257, New York, NY, 10150-5257
CLMN Number of Claims: 115
ECL Exemplary Claim: 1
DRWN 33 Drawing Page(s)
LN.CNT 4966

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to immunogenic but non-depositing-forming polypeptides or peptides homologous to amyloid .beta., prion, amylin or .alpha.-synuclein which can be used alone or conjugated to an immunostimulatory molecule in an immunizing composition for inducing an immune response to amyloid .beta. peptides and amyloid deposits, to prion protein and prion deposits, to amylin and amylin deposits, to .alpha.-synuclein and deposits containing .alpha.-synuclein, or to polyglutamine repeats and deposits of proteins containing polyglutamine repeats. Described are also antibodies directed against such peptides, their generation, and their use in methods of passive immunization to such peptides and deposits.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 33 USPATFULL on STN
AN 2003:184100 USPATFULL
TI Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
IN Lai, Ching-San, Encinitas, CA, United States
Vassilev, Vassil, San Diego, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6589991 B1 20030708
AI US 2000-565665 20000505 (9)
RLI Division of Ser. No. US 1998-103639, filed on 23 Jun 1998, now patented, Pat. No. US 6093743
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weddington, Kevin E.
LREP Reiter, Stephen E., Foley & Lardner
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2498

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel dithiocarbamate disulfide dimer useful in various therapeutic **treatments**, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of) species that induce the expression of nitric oxide synthase to reduce the production of such species, while, at the same time reducing nitric oxide levels in the subject. In another embodiment, free iron ion levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate(s) to scavenge free iron ions, for example, in subjects undergoing anthracycline chemotherapy. In another embodiment, cyanide levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate so as to bind cyanide in the subject. In a further aspect, the present invention relates to compositions and formulations useful in such therapeutic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 33 USPATFULL on STN
AN 2003:127625 USPATFULL
TI Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor
IN Lai, Ching-San, Carlsbad, CA, UNITED STATES

Wang, Tingmin, San Marcos, CA, UNITED STATES
PA Medinox, Inc. (U.S. corporation)
PI US 2003087840 A1 20030508
AI US 2002-176396 A1 20020618 (10)
RLI Division of Ser. No. US 1999-453608, filed on 3 Dec 1999, GRANTED, Pat.
No. US 6407135 Continuation-in-part of Ser. No. WO 1998-US10295, filed
on 19 May 1998, PENDING
DT Utility
FS APPLICATION
LREP FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 2139

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In accordance with the present invention, there are provided conjugates
of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and
pharmacologically active agents (e.g., NSAIDs). Invention conjugates
provide a new class of pharmacologically active agents (e.g.,
anti-inflammatory agents) which cause a much lower incidence of
side-effects due to the protective effects imparted by modifying the
pharmacologically active agents as described herein. In addition,
invention conjugates are more effective than unmodified
pharmacologically active agents because cells and tissues contacted by
the pharmacologically active agent(s) are protected from the potentially
damaging effects of nitric oxide overproduction induced thereby as a
result of the co-production of nitric oxide scavenger (e.g.,
dithiocarbamate), in addition to free pharmacologically active agent,
when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 33 USPATFULL on STN
AN 2003:85867 USPATFULL
TI Oral delivery formulation
IN Compton, Bruce Jon, Lexington, MA, UNITED STATES
Solari, Nancy E., West Newton, MA, UNITED STATES
Flangan, Margaret A., Stow, MA, UNITED STATES
PI US 2003059471 A1 20030327
AI US 2001-997277 A1 20011129 (9)
RLI Continuation of Ser. No. US 1998-55560, filed on 6 Apr 1998, ABANDONED
PRAI US 1997-69501P 19971215 (60)
US 1998-73867P 19980204 (60)
DT Utility
FS APPLICATION
LREP Stephen J Gaudet, 68H Stiles Road, Salem, NH, 03079
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2950

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Flakes containing drugs and methods for forming and using such flakes
are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 33 USPATFULL on STN
AN 2002:273412 USPATFULL
TI Therapeutic methods employing disulfide derivatives of dithiocarbamates
and compositions useful therefor
IN Lai, Ching-San, Encinitas, CA, UNITED STATES
Vassilev, Vassil, San Diego, CA, UNITED STATES
PA Medinox, Inc. (U.S. corporation)
PI US 2002151540 A1 20021017

US 6596770 B2 20030722
AI US 2002-44096 A1 20020111 (10)
RLI Division of Ser. No. US 2000-565665, filed on 5 May 2000, ABANDONED
DT Utility
FS APPLICATION
LREP Stephen E. Reiter, Foley & Lardner, P.O. Box 80278, San Diego, CA,
92138-0278
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 2548

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel dithiocarbamate disulfide dimer useful in various therapeutic **treatments**, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of) species that induce the expression of nitric oxide synthase to reduce the production of such species, while, at the same time reducing nitric oxide levels in the subject. In another embodiment, free iron ion levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate(s) to scavenge free iron ions, for example, in subjects undergoing anthracycline chemotherapy. In another embodiment, cyanide levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate so as to bind cyanide in the subject. In a further aspect, the present invention relates to compositions and formulations useful in such therapeutic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 33 USPATFULL on STN
AN 2002:144299 USPATFULL
TI Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor
IN Lai, Ching-San, Encinitas, CA, United States
Wang, Tingmin, San Marcos, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6407135 B1 20020618
AI US 1999-453608 19991203 (9)
RLI Continuation-in-part of Ser. No. WO 1998-US10295, filed on 19 May 1998
Continuation of Ser. No. US 1997-869158, filed on 4 Jun 1997, now
patented, Pat. No. US 5916910
DT Utility
FS GRANTED
EXNAM Primary Examiner: Davenport, Avis M.
LREP Reiter, Stephen E., Foley & Lardner
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2157

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent,

when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 33 USPATFULL on STN
AN 2002:119915 USPATFULL
TI 1-oxorapamycins
IN Zhu, Tianmin, Monroe, NY, UNITED STATES
PA American Home Products Corporation, Madison, NJ (U.S. corporation)
PI US 2002061903 A1 20020523
US 6399625 B2 20020604
AI US 2001-954880 A1 20010918 (9)
PRAI US 2000-235750P 20000927 (60)
DT Utility
FS APPLICATION
LREP Arnold S. Milowsky, American Home Products Corporation, Patent Law
Department - 2B, Five Giralda Farms, Madison, NJ, 07940
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 854

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides 1-oxorapamycins, which are useful in inducing immunosuppression, as a neurotrophic agent, and in the **treatment** of transplantation rejection, autoimmune diseases, solid tumors, fungal infections, and vascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 33 USPATFULL on STN
AN 2002:105887 USPATFULL
TI Methods and systems for assessing biological materials using optical and spectroscopic detection techniques
IN Hochman, Daryl W., Bahama, NC, UNITED STATES
PI US 2002055092 A1 20020509
US 6573063 B2 20030603
AI US 2001-1366 A1 20011030 (10)
RLI Continuation-in-part of Ser. No. US 2000-629046, filed on 31 Jul 2000, PATENTED Continuation of Ser. No. US 1999-326008, filed on 4 Jun 1999, PATENTED Continuation-in-part of Ser. No. US 1997-949416, filed on 14 Oct 1997, PATENTED Continuation of Ser. No. US 1995-539296, filed on 4 Oct 1995, PATENTED
PRAI US 1998-88494P 19980608 (60)
DT Utility
FS APPLICATION
LREP Ann W. Speckman, SPECKMAN LAW GROUP, Suite 100, 1501 Western Avenue, Seattle, WA, 98101
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 2861

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Optical detection techniques for the assessment of the physiological state, health and/or viability of biological materials are provided. Biological materials which may be examined using such techniques include cells, tissues, organs and subcellular components. The inventive techniques may be employed in high throughput screening of potential diagnostic and/or therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 33 USPATFULL on STN
AN 2002:85531 USPATFULL
TI POLYDITHIOCARBAMATE-CONTAINING NON-TARGETING MACROMOLECULES AND THE USE

THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS
IN LAI, CHING-SAN, ENCINITAS, CA, UNITED STATES
PI US 2002045573 A1 20020418
US 6649591 B2 20031118
AI US 1999-409645 A1 19991001 (9)
RLI Continuation-in-part of Ser. No. US 1997-899087, filed on 23 Jul 1997,
ABANDONED
PRAI US 1996-25867P 19960910 (60)
DT Utility
FS APPLICATION
LREP STEPHEN E REITER, GRAY WARE & FREIDENRICH LLP, 4365 EXECUTIVE DRIVE
SUITE 1600, SAN DIEGO, CA, 921212189
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1763

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In accordance with the present invention, there is provided a new class of drugs for therapeutic **treatment** of such indications as cerebral stroke and other ischemia/reperfusion injury. Thus, in accordance with the present invention, dithiocarbamates are linked to the surface of a non-immunogenic, non-targeting macromolecule other than an antibody (e.g., albumin protein) either by using cross-linking reagents or by nonspecific binding to produce polydithiocarbamate-macromolecule-containing compositions, which represent a new class of drugs for therapeutic **treatment** of such indications as cerebral stroke and other ischemia/reperfusion injury. In accordance with another aspect of the present invention, combinational therapeutic methods have been developed for the in vivo inactivation or inhibition of formation (either directly or indirectly) of species which induce the expression of inducible nitric oxide synthase, as well as reducing nitric oxide levels produced as a result of .NO synthase expression. In accordance with yet another aspect of the present invention, magnetic resonance imaging methods have been developed for the measurement of cerebral and cardiac blood flow and infarct volume in ischemic stroke or heart attack situations. Such methods employ iron-containing complexes of a composition comprising a dithiocarbamate and a non-immunogenic, non-targeting macromolecule other than an antibody as contrast agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 33 USPATFULL on STN
AN 2002:72873 USPATFULL
TI Novel therapeutic use of low molecular weight **heparins**
IN Stutzmann, Jean-Marie, Villecresnes, FRANCE
Uzan, Andre, Paris, FRANCE
PI US 2002040013 A1 20020404
AI US 2001-881267 A1 20010614 (9)
RLI Continuation of Ser. No. WO 1999-FR3109, filed on 13 Dec 1999, UNKNOWN
PRAI FR 1998-15919 19981217
DT Utility
FS APPLICATION
LREP AVENTIS PHARMACEUTICALS, INC., PATENTS DEPARTMENT, ROUTE 202-206, P.O.
BOX 6800, BRIDGEWATER, NJ, 08807-0800
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 331
AB The invention concerns the use of low molecular weight **heparin** for preventing and/or **treating** motor neuron diseases.

L4 ANSWER 20 OF 33 USPATFULL on STN
AN 2002:17328 USPATFULL

TI Dha-pharmaceutical agent conjugates of taxanes
IN Shashoua, Victor, Brookline, MA, UNITED STATES
Swindell, Charles, Merion, PA, UNITED STATES
Webb, Nigel, Bryn Mawr, PA, UNITED STATES
Bradley, Matthews, Layton, PA, UNITED STATES
PI US 2002010208 A1 20020124
US 6602902 B2 20030805
AI US 2001-846838 A1 20010501 (9)
RLI Continuation of Ser. No. US 1998-135291, filed on 17 Aug 1998, ABANDONED
Continuation of Ser. No. US 1996-651312, filed on 22 May 1996, GRANTED,
Pat. No. US 5795909
DT Utility
FS APPLICATION
LREP Edward R. Gates, Esq., Wolf, Greenfield & Sacks, P.C., 600 Atlantic
Avenue, Boston, MA, 02210
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 2437

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in **treating** noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 21 OF 33 USPATFULL on STN
AN 2001:202682 USPATFULL
TI Therapeutic methods employing disulfide derivatives of dithiocarbonates and compositions useful therefor
IN Lai, Ching-San, Encinitas, CA, United States
Vassilev, Vassil, San Diego, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6316502 B1 20011113
AI US 2000-565666 20000505 (9)
RLI Division of Ser. No. US 1998-103639, filed on 23 Jun 1998, now patented, Pat. No. US 6093743
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weddington, Kevin E.
LREP Reiter, Stephen E.Foley & Lardner
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2591

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel dithiocarbamate disulfide dimer useful in various therapeutic **treatments**, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of) species that induce the expression of nitric oxide synthase to reduce the production of such species, while, at the same time reducing nitric oxide levels in the subject. In another embodiment, free iron ion levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate(s) to scavenge free iron ions, for example, in subjects undergoing anthracycline chemotherapy. In another embodiment, cyanide levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate so as to bind cyanide in the subject. In a further aspect, the present invention relates to compositions and formulations useful in such therapeutic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 33 USPATFULL on STN
AN 2001:131342 USPATFULL
TI Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
IN Lai, Ching-San, Encinitas, CA, United States
Vassilev, Vassil P., San Diego, CA, United States
Wang, Tingmin, San Marcos, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6274627 B1 20010814
AI US 1999-416619 19991012 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weddington, Kevin E.
LREP Reiter, Stephen E. Foley & Lardner
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2173

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In accordance with the present invention, there are provided conjugates of physiologically compatible free radical scavengers (e.g., dithiocarbamate disulfides (DD)) and pharmacologically active agents (e.g., NSAIDS). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of free radical overproduction induced thereby as a result of the co-production of free radical scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 23 OF 33 USPATFULL on STN
AN 2001:90260 USPATFULL
TI Fatty acid-pharmaceutical agent conjugates
IN Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
Swindell, Charles S., Merion, PA, United States
Shashoua, Victor E., Brookline, MA, United States
PI US 2001002404 A1 20010531
US 6576636 B2 20030610
AI US 2000-730450 A1 20001205 (9)
RLI Continuation of Ser. No. US 1996-651428, filed on 22 May 1996, ABANDONED
DT Utility
FS APPLICATION
LREP Edward R. Gates, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 2511

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of fatty acids and pharmaceutical agents useful in **treating** noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 24 OF 33 USPATFULL on STN
AN 2000:95042 USPATFULL
TI Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
IN Lai, Ching-San, Encinitas, CA, United States
Vassilev, Vassil, San Diego, CA, United States
PA Medinox Inc., San Diego, CA, United States (U.S. corporation)
PI US 6093743 20000725
AI US 1998-103639 19980623 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Weddington, Kevin E.
LREP Gary Cary Ware & Freidenrich, Reiter, Stephen E., Kirschenbaum, Shelia R.
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2691

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel dithiocarbamate disulfide dimer useful in various therapeutic **treatments**, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of) species that induce the expression of nitric oxide synthase to reduce the production of such species, while, at the same time reducing nitric oxide levels in the subject. In another embodiment, free iron ion levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate(s) to scavenge free iron ions, for example, in subjects undergoing anthracycline chemotherapy. In another embodiment, cyanide levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate so as to bind cyanide in the subject. In a further aspect, the present invention relates to compositions and formulations useful in such therapeutic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 25 OF 33 USPATFULL on STN
AN 1999:72602 USPATFULL
TI Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
IN Lai, Ching-San, Encinitas, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 5916910 19990629
AI US 1997-869158 19970604 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Davis, Zinna Northington
LREP Reiter, Esq., Stephen E.Gray, Cary, Ware & Freidenrich
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1842

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially

damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 26 OF 33 USPATFULL on STN
AN 1998:98932 USPATFULL
TI DHA-pharmaceutical agent conjugates of taxanes
IN Shashoua, Victor E., Brookline, MA, United States
Swindell, Charles S., Merion, PA, United States
Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
PA Neuromedica, Inc., Conshohocken, PA, United States (U.S. corporation)
PI US 5795909 19980818
AI US 1996-651312 19960522 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Jarvis, William R. A.
LREP Wolf, Greenfield & Sacks, P.C.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 27 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 2451

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and taxanes useful in **treating** cell proliferative disorders. Conjugates of paclitaxel and docetaxel are preferred.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 27 OF 33 USPAT2 on STN
AN 2002:273412 USPAT2
TI Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
IN Lai, Ching-San, Encinitas, CA, United States
Vassilev, Vassil, San Diego, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6596770 B2 20030722
AI US 2002-44096 20020111 (10)
RLI Division of Ser. No. US 2000-565665, filed on 5 May 2000, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weddington, Kevin E.
LREP Reiter, Stephen E., Foley & Lardner
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2550

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel dithiocarbamate disulfide dimer useful in various therapeutic **treatments**, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of) species that induce the expression of nitric oxide synthase to reduce the production of such species, while, at the same time reducing nitric oxide levels in the subject. In another embodiment, free iron ion levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate(s) to scavenge free iron ions, for example, in subjects undergoing anthracycline chemotherapy. In another embodiment, cyanide levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate so as to bind cyanide in the subject. In

a further aspect, the present invention relates to compositions and formulations useful in such therapeutic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 28 OF 33 USPAT2 on STN
AN 2002:119915 USPAT2
TI 1-oxorapamycins
IN Zhu, Tianmin, Monroe, NY, United States
PA Wyeth, Madison, NJ, United States (U.S. corporation)
PI US 6399625 B2 20020604
AI US 2001-954880 20010918 (9)
PRAI US 2000-235750P 20000927 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Kifle, Bruck
LREP Milowsky, Arnold S.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 704

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides 1-oxorapamycins, which are useful in inducing immunosuppression, as a neurotrophic agent, and in the **treatment** of transplantation rejection, autoimmune diseases, solid tumors, fungal infections, and vascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 29 OF 33 USPAT2 on STN
AN 2002:105887 USPAT2
TI Methods and systems for assessing biological materials using optical and spectroscopic detection techniques
IN Hochman, Daryl W., Bahama, NC, United States
PA Cytoscan Sciences, LLC, Seattle, WA, United States (U.S. corporation)
PI US 6573063 B2 20030603
AI US 2001-1366 20011030 (10)
RLI Continuation-in-part of Ser. No. US 2000-629046, filed on 31 Jul 2000, now patented, Pat. No. US 6319682, issued on 20 Nov 2001 Continuation of Ser. No. US 1999-326008, filed on 4 Jun 1999, now patented, Pat. No. US 6096510, issued on 1 Aug 2000 Continuation-in-part of Ser. No. US 1997-949416, filed on 14 Oct 1997, now patented, Pat. No. US 5976825, issued on 2 Nov 1999 Continuation of Ser. No. US 1995-539296, filed on 4 Oct 1995, now patented, Pat. No. US 5902732, issued on 11 May 1999
PRAI US 1998-88494P 19980608 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Leary, Louise N.
LREP Speckman, Ann W., Sleath, Janet
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 45 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 2899

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Optical detection techniques for the assessment of the physiological state, health and/or viability of biological materials are provided. Biological materials which may be examined using such techniques include cells, tissues, organs and subcellular components. The inventive techniques may be employed in high throughput screening of potential diagnostic and/or therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 30 OF 33 USPAT2 on STN

AN 2002:85531 USPAT2
TI Polydithiocarbamate-containing non-targeting macromolecules and the use thereof for therapeutic and diagnostic applications
IN Lai, Ching-San, Encinitas, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6649591 B2 20031118
AI US 1999-409645 19991001 (9)
RLI Continuation-in-part of Ser. No. US 1997-899087, filed on 23 Jul 1997, now abandoned
PRAI US 1996-25867P 19960910 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Saunders, David
LREP Reiter, Stephen E., Foley & Lardner
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1764

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In accordance with the present invention, there is provided a new class of drugs for therapeutic **treatment** of such indications as cerebral stroke and other ischemia/reperfusion injury. Thus, in accordance with the present invention, dithiocarbamates are linked to the surface of a non-immunogenic, non-targeting macromolecule other than an antibody (e.g., albumin protein) either by using cross-linking reagents or by nonspecific binding to produce polydithiocarbamate-macromolecule-containing compositions, which represent a new class of drugs for therapeutic **treatment** of such indications as cerebral stroke and other ischemia/reperfusion injury. In accordance with another aspect of the present invention, combinational therapeutic methods have been developed for the in vivo inactivation or inhibition of formation (either directly or indirectly) of species which induce the expression of inducible nitric oxide synthase, as well as reducing nitric oxide levels produced as a result of .NO synthase expression. In accordance with yet another aspect of the present invention, magnetic resonance imaging methods have been developed for the measurement of cerebral and cardiac blood flow and infarct volume in ischemic stroke or heart attack situations. Such methods employ iron-containing complexes of a composition comprising a dithiocarbamate and a non-immunogenic, non-targeting macromolecule other than an antibody as contrast agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 31 OF 33 USPAT2 on STN
AN 2002:17328 USPAT2
TI Dha-pharmaceutical agent conjugates to improve tissue selectivity
IN Shashoua, Victor E., Brookline, MA, United States
Swindell, Charles E., Merion, PA, United States
Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Layton, PA, United States
PA Protarga, Inc., King of Prussia, PA, United States (U.S. corporation)
PI US 6602902 B2 20030805
AI US 2001-846838 20010501 (9)
RLI Continuation of Ser. No. US 1998-135291, filed on 17 Aug 1998, now abandoned Continuation of Ser. No. US 1996-651312, filed on 22 May 1996, now patented, Pat. No. US 5795909
DT Utility
FS GRANTED
EXNAM Primary Examiner: Krass, Frederick; Assistant Examiner: Jagoe, Donna
LREP Wolf, Greenfield, & Sacks, P.C.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 27 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 2583

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in **treating** noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 32 OF 33 USPAT2 on STN
AN 2001:90260 USPAT2
TI Method of **treating** a liver disorder with fatty acid-antiviral agent conjugates
IN Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
Swindell, Charles S., Merion, PA, United States
Shashoua, Victor E., Brookline, MA, United States
PA Protarga, Inc., King of Prussia, PA, United States (U.S. corporation)
PI US 6576636 B2 20030610
AI US 2000-730450 20001205 (9)
RLI Continuation of Ser. No. US 1996-651428, filed on 22 May 1996, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Jarvis, William R. A.
LREP Wolf, Greenfield & Sacks, P.C.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 27 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 2654

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of fatty acids and antiviral agents useful in **treating** liver disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 33 OF 33 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN
AN 92054425 EMBASE
DN 1992054425
TI Prevention of thromboembolism after spinal cord injury.
AU Green D.
CS Rehabilitation Inst. Chicago, 345 E. Superior Street, Chicago, IL 60611, United States
SO Seminars in Thrombosis and Hemostasis, (1991) 17/4 (347-350).
ISSN: 0094-6176 CODEN: STHMBV
CY United States
DT Journal; Conference Article
FS 015 Chest Diseases, Thoracic Surgery and Tuberculosis
025 Hematology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
AB Thromboembolism is a major cause of morbidity and mortality in patients with spinal cord injury. The prevalence of DVT approaches 100%, and 1 to 2% will die of PE. Following injury, there is hypercoagulability as reflected by an increase in von Willebrand factor activity and antigen, and increased platelet reactivity to collagen. Thrombosis usually occurs 1 to 3 weeks after injury, with a peak between days 7 and 9. Intermittent calf compression boots reduce the frequency of thrombosis to 40%, and the addition of aspirin, 300 mg twice daily, and dipyridamole, 75 mg thrice daily, decrease this further to 25%. In an attempt to provide more effective prophylaxis, a further trial was conducted using **heparin**. Twenty-nine patients were randomized to receive 5000 U subcutaneously

every 12 hours and compared with an equal number of patients **treated** with doses of **heparin** adjusted to prolong the APTT to 1.5 times control values; the mean dose was 13,200 U every 12 hours. Thromboembolism occurred in 9 (31%) of those on the fixed dose (6 VDT and 3 PE) and only 2 (7%) on the adjusted dose ($p < 0.05$); however, 7 (24%) of the patients receiving the higher doses of **heparin** had bleeding compared with none of those on the fixed dose ($p < 0.02$). Most recently, we have compared the safety and effectiveness of a low molecular weight **heparin** (Logiparin, Novo) with standard **heparin**. The former was given once daily in a dose of 3500 anti-Xa units, and the latter was 5000 U every 8 hours, both given subcutaneously. No thrombosis or bleeding occurred in 20 Logiparin-**treated** patients, whereas 5 of 21 receiving standard **heparin** had thrombosis, including two with fatal PE, and two additional patients had bleeding. This difference in event rate between the two **treatments** was statistically significant ($p < 0.02$). We conclude that thromboprophylaxis with a low molecular weight **heparin** (Logiparin) offers great promise in the management of patients with spinal cord injury.

=> dis hist

(FILE 'HOME' ENTERED AT 08:50:27 ON 03 DEC 2003)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, DISSABS, EMA, IFIPAT, JICST-EPLUS, PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2, WPINDEX, WTEXTILES, MEDLINE, BIOSIS, EMBASE' ENTERED AT 08:50:52 ON 03 DEC 2003

```
L1      326717 S HEPARIN
L2      1679 S L1 AND (MOTONEURON OR AMYOTROPH?(W)SCLEROSIS OR MUSCULAR(W)A
L3      1618 S L2 AND TREAT?
L4      33 S L3 AND (ENOXAPARIN OR NADROPARIN OR PARNAPARIN OR REVIPARIN
```

=> l3 and low(w)molecular(w)weight

L3 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l3 and low(W)molecular(w)weight

16 FILES SEARCHED...

```
L5      650 L3 AND LOW(W) MOLECULAR(W) WEIGHT
```

=> s l5 and O-sulfo-4-enopyranosuronic

19 FILES SEARCHED...

```
L6      3 L5 AND O-SULFO-4-ENOPYRANOSURONIC
```

=> dis l6 1-3 bib abs

```
L6      ANSWER 1 OF 3  IFIPAT  COPYRIGHT 2003 IFI on STN
AN      10096447  IFIPAT;IFIUDB;IFICDB
TI      NOVEL THERAPEUTIC USE OF LOW MOLECULAR WEIGHT
        HEPARINS; LOW MOLECULAR WEIGHT
        HEPARIN CONSISTS OF OLIGOSACCHARIDES HAVING A 2-O-
        SULFO-4-ENOPYRANOSURONIC ACID AT ONE OF THEIR
        ENDS AND OBTAINED BY DEPOLYMERIZATION OF A HEPARIN ESTER USING
        SODIUM HYDROXIDE BASE; USEFUL FOR TREATING MUSCULAR
        ATROPHY
INF     Stutzmann; Jean-Marie, Villecresnes, FR
        Uzan; Andre, Paris, FR
IN      Stutzmann Jean-Marie (FR); Uzan Andre (FR)
PAF     Unassigned
PA      Unassigned Or Assigned To Individual (68000)
AG      AVENTIS PHARMACEUTICALS, INC. PATENTS DEPARTMENT, ROUTE 202-206, P.O. BOX
```

6800, BRIDGEWATER, NJ, 08807-0800, US

PI US 2002040013 A1 20020404
 AI US 2001-881267 20010614
 PRAI FR 1998-15919 19981217
 FI US 2002040013 20020404
 DT Utility; Patent Application - First Publication
 FS CHEMICAL
 APPLICATION

CLMN 19
 AB The invention concerns the use of **low molecular weight heparin** for preventing and/or **treating** motor neuron diseases.

CLMN 19

L6 ANSWER 2 OF 3 USPATFULL on STN
 AN 2002:72873 USPATFULL
 TI Novel therapeutic use of **low molecular weight heparins**
 IN Stutzmann, Jean-Marie, Villecresnes, FRANCE
 Uzan, Andre, Paris, FRANCE
 PI US 2002040013 A1 20020404
 AI US 2001-881267 A1 20010614 (9)
 RLI Continuation of Ser. No. WO 1999-FR3109, filed on 13 Dec 1999, UNKNOWN
 PRAI FR 1998-15919 19981217
 DT Utility
 FS APPLICATION
 LREP AVENTIS PHARMACEUTICALS, INC., PATENTS DEPARTMENT, ROUTE 202-206, P.O. BOX 6800, BRIDGEWATER, NJ, 08807-0800
 CLMN Number of Claims: 19
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 331
 AB The invention concerns the use of **low molecular weight heparin** for preventing and/or **treating** motor neuron diseases.

L6 ANSWER 3 OF 3 WPINDEX COPYRIGHT 2003 THOMSON DERWENT on STN
 AN 2000-442268 [38] WPINDEX
 DNC C2000-134436
 TI Use of **low molecular weight heparin** for **treatment** and prevention of motor neuron disease, e.g. amyotrophic **lateral sclerosis**.

DC B04
 IN STUTZMANN, J M; UZAN, A; STUTZMANN, J
 PA (AVET) AVENTIS PHARMA SA; (STUT-I) STUTZMANN J; (UZAN-I) UZAN A
 CYC 83
 PI WO 2000035462 A1 20000622 (200038)* FR 18p
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SL SZ TZ UG ZW
 W: AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS
 JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO RU SG SI SK SL
 TR TT UA US UZ VN YU ZA
 FR 2787329 A1 20000623 (200038)
 AU 2000015697 A 20000703 (200046)
 NO 2001002849 A 20010608 (200154)
 EP 1140119 A1 20011010 (200167) FR
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI
 US 2002040013 A1 20020404 (200227)
 JP 2002532431 W 20021002 (200279) 19p

ADT WO 2000035462 A1 WO 1999-FR3109 19991213; FR 2787329 A1 FR 1998-15919 19981217; AU 2000015697 A AU 2000-15697 19991213; NO 2001002849 A WO 1999-FR3109 19991213, NO 2001-2849 20010608; EP 1140119 A1 EP 1999-958308

19991213, WO 1999-FR3109 19991213; US 2002040013 A1 Cont of WO 1999-FR3109
 19991213, US 2001-881267 20010614; JP 2002532431 W WO 1999-FR3109
 19991213, JP 2000-587782 19991213
 FDT AU 2000015697 A Based on WO 2000035462; EP 1140119 A1 Based on WO
 2000035462; JP 2002532431 W Based on WO 2000035462
 PRAI FR 1998-15919 19981217
 AN 2000-442268 [38] WPINDEX
 AB WO 200035462 A UPAB: 20000811
 NOVELTY - Use of **low molecular weight**
heparin (I) to produce a medicine that promotes survival and/or
 growth of motor neurons.
 ACTIVITY - Cytoprotective; neurotrophic.
 A mixed culture of astrocytes and motor neurons (MN) was
treated with the **low molecular weight**
heparin Enoxaparine (Ia), then after 2-3 days the number of viable
 MN assessed from:
 (i) immunoreactivity for the homoprotein Islet1/2 or for
 neurofilaments; and
 (ii) presence of neurites longer than 10 cell diameters.
 At 10 ng/ml (Ia), the mean number of MN was 196% and the mean MN
 survival was 120.7%, both relative to a vehicle-only control as 100%. The
 number of very large MN was 66 per cubic centimeters (cc) in presence of
 (Ia) compared with 38 per cc in a control.
 MECHANISM OF ACTION - None given.
 No biological data given.
 USE - (I) is specifically used to **treat** and/or prevent
 motor neuron diseases, particularly amyotrophic **lateral**
sclerosis, progressive spinal **muscular atrophy**
 and infantile **muscular atrophy**.
 Dwg.0/0

=> dis hist

(FILE 'HOME' ENTERED AT 08:50:27 ON 03 DEC 2003)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, DISSABS, EMA, IFIPAT,
 JICST-EPLUS, PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH,
 USPATFULL, USPAT2, WPINDEX, WTEXTILES, MEDLINE, BIOSIS, EMBASE' ENTERED
 AT 08:50:52 ON 03 DEC 2003

L1 326717 S HEPARIN
 L2 1679 S L1 AND (MOTONEURON OR AMYOTROPH? (W) SCLEROSIS OR MUSCULAR (W) A
 L3 1618 S L2 AND TREAT?
 L4 33 S L3 AND (ENOXAPARIN OR NADROPARIN OR PARNAPARIN OR REVIPARIN
 L5 650 S L3 AND LOW (W) MOLECULAR (W) WEIGHT
 L6 3 S L5 AND O-SULFO-4-ENOPYRANOSURONIC